World J Gastroenterol. 2013 Mar 14;19(10):1671-2. doi: 10.3748/wjg.v19.i10.1671.
The selection of antiviral drugs for chronic hepatitis B (CHB) treatment in pregnancy is very difficult since none of the drugs have been approved for use in pregnancy. Transmission from mother to newborn remains the most frequent route of infection in mothers with high viral load and positive hepatitis B e antigen status, even with the use of appropriate prophylaxis with hepatitis B virus (HBV) immunoglobulin and HBV vaccination. We read from the article written by Yi et al that lamivudine treatment in early pregnancy was safe and effective. However, we could not understand why adefovir dipivoxil (ADV) was used in three pregnancy cases, since ADV has been classified as pregnancy category C. In pregnancy, telbivudine or tenofovir should be selected when the treatment of CHB is necessary, since these drugs have been classified as Food and Drug Administration pregnancy risk category B.
在妊娠期间，慢性乙型肝炎（CHB）的抗病毒药物选择非常困难，因为没有一种药物被批准用于妊娠。即使使用乙型肝炎病毒（HBV）免疫球蛋白和 HBV 疫苗进行适当的预防，在高病毒载量和 HBeAg 阳性的母亲中，母婴传播仍然是最常见的感染途径。我们从 Yi 等人撰写的文章中了解到，孕早期使用拉米夫定治疗是安全有效的。然而，我们不理解为什么在三个妊娠病例中使用阿德福韦酯（ADV），因为 ADV 被归类为妊娠 C 类药物。在需要治疗 CHB 的情况下，应选择替比夫定或替诺福韦，因为这些药物被归类为美国食品和药物管理局妊娠风险类别 B。
